Leonard J. Appleman

6.2k total citations
178 papers, 3.3k citations indexed

About

Leonard J. Appleman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Leonard J. Appleman has authored 178 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Pulmonary and Respiratory Medicine, 94 papers in Oncology and 46 papers in Molecular Biology. Recurrent topics in Leonard J. Appleman's work include Renal cell carcinoma treatment (44 papers), Cancer Immunotherapy and Biomarkers (43 papers) and Prostate Cancer Treatment and Research (42 papers). Leonard J. Appleman is often cited by papers focused on Renal cell carcinoma treatment (44 papers), Cancer Immunotherapy and Biomarkers (43 papers) and Prostate Cancer Treatment and Research (42 papers). Leonard J. Appleman collaborates with scholars based in United States, Germany and Spain. Leonard J. Appleman's co-authors include Vassiliki A. Boussiotis, André A. F. L. van Puijenbroek, Toni K. Choueiri, Alla Berezovskaya, Rahul Atul Parikh, Isabelle Grass, Lee M. Nadler, Kirstin M. Shu, Joseph P. Eder and Jan H. Beumer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Leonard J. Appleman

172 papers receiving 3.3k citations

Peers

Countries citing papers authored by Leonard J. Appleman

Since Specialization

Citations

This map shows the geographic impact of Leonard J. Appleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leonard J. Appleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leonard J. Appleman more than expected).

Fields of papers citing papers by Leonard J. Appleman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leonard J. Appleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leonard J. Appleman. The network helps show where Leonard J. Appleman may publish in the future.

Co-authorship network of co-authors of Leonard J. Appleman

This figure shows the co-authorship network connecting the top 25 collaborators of Leonard J. Appleman. A scholar is included among the top collaborators of Leonard J. Appleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leonard J. Appleman. Leonard J. Appleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bench-to-Bedside Evaluation of Sulforaphane/BroccoMax on Fatty Acid Synthesis in Prostate Cancer 2026 ·Cancer Prevention Research ·(unknown), Karen M. Kuntz, Krishna B. Singh, (unknown), (unknown), Daniel P. Normolle, (unknown), (unknown), (unknown), (unknown), Leonard J. Appleman, (unknown), (unknown)	0
2	Updated follow up of a randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC). 2025 ·Journal of Clinical Oncology ·(unknown), Charlene Thomas, (unknown), (unknown), Yousef Zakharia, Leonard J. Appleman, Joseph R. Osborne, George Philips, Luke T. Nordquist, Anishka D'souza, Elizabeth Wulff‐Burchfield, Edwin M. Posadas, Neeraj Agarwal, Paul J. Christos, Nabil Adra, David M. Nanus, Scott T. Tagawa	0
3	1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study 2024 ·Annals of Oncology ·William Kevin Kelly, Leonard J. Appleman, C-C. Lin, (unknown), Sabine Fischer, David Pook, (unknown), Jia-Lin Lee, (unknown), Phil Ward, (unknown), Lisa G. Horvath, (unknown), (unknown), Christopher Sumey, (unknown), Zhi Yang, Jamie N. Connarn, Julia Stieglmaier, Daniel C. Danila	1
4	264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) 2023 ·Annals of Oncology ·William Kevin Kelly, Daniel C. Danila, C-C. Lin, Jia-Lin Lee, Nobuaki Matsubara, Phil Ward, Andrew J. Armstrong, David Pook, (unknown), Tanya B. Dorff, Stefanie Fischer, (unknown), Lisa G. Horvath, Christopher Sumey, Zhi Yang, (unknown), Jamie N. Connarn, Hugo A. Penny, Julia Stieglmaier, Leonard J. Appleman	1
5	Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma 2023 ·Clinical Cancer Research ·Daniel P. Petrylak, Bernhard J. Eigl, Saby George, Elisabeth I. Heath, Sébastien J. Hotte, David D. Chism, Lisle M. Nabell, Joel Picus, Susanna Y. Cheng, Leonard J. Appleman, Guru Sonpavde, Alicia K. Morgans, (unknown), (unknown), (unknown), (unknown), Evan Y. Yu	2
6	Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score 2023 ·European Urology ·Matthew D. Galsky, Dean F. Bajorin, J. Alfred Witjes, Jürgen E. Gschwend, Yoshihiko Tomita, Federico Nasroulah, (unknown), Sandra Collette, Begoña P. Valderrama, Marc‐Oliver Grimm, Leonard J. Appleman, Gwénaëlle Gravis, Andrea Necchi, Dingwei Ye, Frank Stenner, Megan Wind‐Rotolo, Joshua Zhang, Keziban Ünsal-Kaçmaz	14
7	A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer 2021 ·Clinical Cancer Research ·Lawrence Fong, Michael J. Morris, Oliver Sartor, Celestia S. Higano, Lance C. Pagliaro, Ajjai Alva, Leonard J. Appleman, Winston Tan, Ulka N. Vaishampayan, (unknown), Darren Tayama, Edward E. Kadel, Kobe Yuen, (unknown), Andrew J. Armstrong, Daniel P. Petrylak	33
8	Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors 2021 ·Cancer Chemotherapy and Pharmacology ·William F. Maguire, John C. Schmitz, (unknown), (unknown), (unknown), (unknown), Shaoyu Wu, Lin Huang, Shannon Puhalla, John C. Rhee, Ronald G. Stoller, Hussein A. Tawbi, James J. Lee, James R. Wright, Jan H. Beumer, Edward Chu, Leonard J. Appleman, (unknown)	4
9	625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update 2020 ·Annals of Oncology ·Loı̈c Mourey, Henry Jacob Conter, Neal D. Shore, William L. Berry, Peter C.C. Fong, Josep M. Piulats, Leonard J. Appleman, (unknown), Gwénaëlle Gravis, Brigitte Laguerre, Howard Gurney, Margitta Retz, Emanuela Romano, Johann S. de Bono, Audrey E. Kam, Urban Emmenegger, Hao‐Hua Wu, Ping Qiu, Charles Schloss, Evan Y. Yu	4
10	620P Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)–pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update 2020 ·Annals of Oncology ·Emanuela Romano, Srikala S. Sridhar, Michael Kolinsky, Gwénaëlle Gravis, Loı̈c Mourey, Josep M. Piulats, William L. Berry, Howard Gurney, Margitta Retz, Leonard J. Appleman, Martin Boegemann, Johann S. de Bono, Anthony M. Joshua, Urban Emmenegger, Henry Jacob Conter, Brigitte Laguerre, (unknown), Ping Qiu, Charles Schloss, Evan Y. Yu	3
11	217O Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study 2020 ·Annals of Oncology ·Anthony M. Joshua, Howard Gurney, Margitta Retz, Ali Tafreshi, Peter C.C. Fong, Neal D. Shore, Emanuela Romano, Marinela Augustin, Josep M. Piulats, William L. Berry, Michael Kolinsky, Srikala S. Sridhar, Henry Jacob Conter, (unknown), Leonard J. Appleman, Haiyan Wu, Charles Schloss, Christian Poehlein, Johann S. de Bono, Evan Y. Yu	3
12	Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma 2019 ·Clinical Cancer Research ·Naomi B. Haas, Leonard J. Appleman, Mark N. Stein, Maryann Redlinger, (unknown), Xiaowei Xu, Angelique Onorati, (unknown), Tae Hyong Kim, Chao Jie Zhen, Sabah Kadri, Jeremy P. Segal, Phyllis A. Gimotty, Lisa E. Davis, Ravi K. Amaravadi	112
13	Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial 2019 ·Cancer Chemotherapy and Pharmacology ·Thehang Luu, Paul Frankel, Jan H. Beumer, Dean Lim, Mihaela Cristea, Leonard J. Appleman, Heinz Josef Lenz, David R. Gandara, Brian F. Kiesel, Richard Piekarz, Edward M. Newman	11
14	Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial 2018 ·Journal of Clinical Oncology ·Bernard Escudier, Thomas Powles, Robert J. Motzer, Thomas Olencki, Osvaldo Arén Frontera, Stéphane Oudard, Frédéric Rolland, Piotr Tomczak, Daniel Castellano, Leonard J. Appleman, Harry A. Drabkin, Daniel A. Vaena, Steven Milwee, (unknown), Julie C. Lougheed, Sergio Bracarda, Toni K. Choueiri	121
15	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model 2017 ·The Oncologist ·Guillermo de Velasco, Aedín C. Culhane, André P. Fay, A. Ari Hakimi, Martin H. Voss, Nizar M. Tannir, Pheroze Tamboli, Leonard J. Appleman, Joaquim Bellmunt, W. Kimryn Rathmell, Laurence Albigès, James J. Hsieh, Daniel Y.C. Heng, Sabina Signoretti, Toni K. Choueiri	49
16	A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent 2014 ·Clinical Cancer Research ·Leonard J. Appleman, Sanjeeve Balasubramaniam, Robert A. Parise, (unknown), Christophe E. Redon, Asako Nakamura, William M. Bonner, James R. Wright, Richard Piekarz, David Köhler, Yixing Jiang, Chandra P. Belani, Julie L. Eiseman, Edward Chu, Jan H. Beumer, Susan E. Bates	5
17	Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure 2011 ·European Journal of Cancer ·Nizar M. Tannir, (unknown), Christian Kollmannsberger, Marc S. Ernstoff, David J. Perry, Leonard J. Appleman, Edwin M. Posadas, Daniel Cho, Toni K. Choueiri, A. Coates, Neeraj Gupta, Rajendra Pradhan, Jiang Qian, Jihong Chen, Frank A. Scappaticci, Justin L. Ricker, Dawn M. Carlson, M. Dror Michaelson	24
18	Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors 2006 ·Cancer Chemotherapy and Pharmacology ·A. Craig Lockhart, Ronald M. Bukowski, Mace L. Rothenberg, (unknown), Wendy Cooper, J.K Grover, Leonard J. Appleman, (unknown), Mark Shapiro, Aiping Zhu	20
19	Differential Localization and Function of ADP-Ribosylation Factor-6 in Anergic Human T Cells: A Potential Marker for Their Identification 2003 ·The Journal of Immunology ·Dimitrios Tzachanis, Leonard J. Appleman, André A. F. L. van Puijenbroek, Alla Berezovskaya, Lee M. Nadler, Vassiliki A. Boussiotis	5
20	CD28 Costimulation Mediates T Cell Expansion Via IL-2-Independent and IL-2-Dependent Regulation of Cell Cycle Progression 2000 ·The Journal of Immunology ·Leonard J. Appleman, Alla Berezovskaya, Isabelle Grass, Vassiliki A. Boussiotis	165

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact